Meilleure Health International Industry Group Limited provided earnings guidance for the six months ended 30 June 2022. For the period, the company expects to record a profit attributable to the Shareholders of approximately HKD 10.6 million as compared to a profit attributable to the Shareholders of approximately HKD 43.2 million for the six months ended 30 June 2021. Such expected decrease is mainly due to the following reasons: a significant unrealized decline in fair values on investments at fair value through profit or loss as a result of adverse market conditions; a decrease in segment profit from agency service and trading business as a result of the overall downturn in the real estate market of mainland China; a decrease in segment profit from industrial hemp business as a result of the prohibition of the use of industrial hemp in all cosmetics in mainland China; the absence of the one-off significant gain on deemed partial disposal of investment in a joint venture recorded during the six months ended 30 June 2021; a material decline in revaluation gain of investment properties of the Group.

This is mainly because of the slowing-down economic growth in mainland China resulting from the outbreak of 2019 novel coronavirus disease; net off with an increase in segment profit from healthcare-related business, which mainly benefited from the sale of skincare products under the Group's brand "Jixiaojian" launched in the second half of the year 2021.